Characterization of DDRI-18 (3,3'-(1H,3'H-5,5'-bibenzo[d]imidazole-2,2'-diyl)dianiline), a novel small molecule inhibitor modulating the DNA damage response.
about
Ouabain, a cardiac glycoside, inhibits the Fanconi anemia/BRCA pathway activated by DNA interstrand cross-linking agentsDDRI-9: a novel DNA damage response inhibitor that blocks mitotic progressionThe checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
P2860
Characterization of DDRI-18 (3,3'-(1H,3'H-5,5'-bibenzo[d]imidazole-2,2'-diyl)dianiline), a novel small molecule inhibitor modulating the DNA damage response.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Characterization of DDRI-18 (3 ...... ating the DNA damage response.
@ast
Characterization of DDRI-18 (3 ...... ating the DNA damage response.
@en
Characterization of DDRI-18 (3 ...... ating the DNA damage response.
@nl
type
label
Characterization of DDRI-18 (3 ...... ating the DNA damage response.
@ast
Characterization of DDRI-18 (3 ...... ating the DNA damage response.
@en
Characterization of DDRI-18 (3 ...... ating the DNA damage response.
@nl
prefLabel
Characterization of DDRI-18 (3 ...... ating the DNA damage response.
@ast
Characterization of DDRI-18 (3 ...... ating the DNA damage response.
@en
Characterization of DDRI-18 (3 ...... ating the DNA damage response.
@nl
P2093
P2860
P1476
Characterization of DDRI-18 (3 ...... ating the DNA damage response.
@en
P2093
P2860
P304
P356
10.1111/J.1476-5381.2012.01977.X
P407
P577
2012-09-01T00:00:00Z